Delving into the Latest Updates on The National Academy of Sciences of Belarus with Synapse

Overview

Tags

Congenital Disorders

Eye Diseases

Skin and Musculoskeletal Diseases

Stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Stem cell therapy	2

BACKGROUNDTrichobakin (TBK), a member of type I ribosome-inactivating proteins (RIPs), was first successfully cloned from Trichosanthes sp Bac Kan 8-98 in Vietnam. Previous study has shown that TBK acts as a potential protein synthesis inhibitor; however, the inhibition efficiency and specificity of TBK on cancer cells remain to be fully elucidated.METHODS AND RESULTSIn this work, we employed TBK and TBK conjugated with a part of the amino-terminal fragment (ATF) of the urokinase-type plasminogen activator (uPA), which contains the Ω-loop that primarily interacts with urokinase-type plasminogen activator receptor, and can be a powerful carrier in the drug delivery to cancer cells. Four different human tumor cell lines and BALB/c mice bearing Lewis lung carcinoma cells (LLC) were used to evaluate the role of TBK and ATF-TBK in the inhibition of tumor growth. Here we showed that the obtained ligand fused RIP (ATF-TBK) reduced the growth of four human cancer cell lines in vitro in the uPA receptor level-dependent manner, including the breast adenocarcinoma MDA-MB 231 cells and MCF7 cells, the prostate carcinoma LNCaP cells and the hepatocellular carcinoma HepG2 cells. Furthermore, the conjugate showed anti-tumor activity and prolonged the survival time of tumor-bearing mice. The ATF-TBK also did not cause the death of mice with doses up to 48 mg/kg, and they were not significantly distinct on parameters of hematology and serum biochemistry between the control and experiment groups.CONCLUSIONSIn conclusion, ATF-TBK reduced the growth of four different human tumor cell lines and inhibited lung tumor growth in a mouse model with little side effects. Hence, the ATF-TBK may be a target to consider as an anti-cancer agent for clinical trials.

01 Nov 2024·IEEE Transactions on Industrial Electronics

Efficient Power Splitting and Conversion in Ferrite/Piezoelectric Transformer Magnetoelectric Composites

Author: Poddubnaya, Natallia ; Filippov, Dmitry ; Du, Jinbo ; Zhang, Jitao ; Jiang, Liying ; Zhang, Qingfang ; Cao, Lingzhi ; Tao, Jiagui

01 Oct 2024·Biochemical and Biophysical Research Communications

Scyllatoxin-based peptide design for E. coli expression and HIV gp120 binding

Article

Author: Park, Kwang-Hyun ; Ahn, Woo-Chan ; Sayyed, Nilofar Danishmalik ; Batyanovskii, Alexander V ; Talwar, Chandana S ; Tuzikov, Alexander V ; Ha, Kwon-Soo ; Woo, Eui-Jeon ; Nurheibah, Salsabilla Izzah

Targeting the hydrophobic Phe43 pocket of HIV's envelope glycoprotein gp120 is a critical strategy for antiviral interventions due to its role in interacting with the host cell's CD4. Previous inhibitors, including small molecules and CD4 mimetic peptides based on scyllatoxin, have demonstrated significant binding and neutralization capabilities but were often chemically synthesized or contained non-canonical amino acids. Microbial expression using natural amino acids offers advantages such as cost-effectiveness, scalability, and efficient production of fusion proteins. In this study, we enhanced the previous scyllatoxin-based synthetic peptide by substituting natural amino acids and successfully expressed it in E. coli. The peptide was optimized by mutating the C-terminal amidated valine to valine and glutamine, and by reducing the disulfide bonds from three to two. Circular dichroism confirmed proper secondary structure formation, and fluorescence polarization analysis revealed specific, concentration-dependent binding to HIV gp120, supported by molecular dynamics simulations. These findings indicate the potential for scalable microbial production of effective antiviral peptides, with significant applications in pharmaceutical development for HIV treatment.

100 Deals associated with The National Academy of Sciences of Belarus

Login to view more data

100 Translational Medicine associated with The National Academy of Sciences of Belarus

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Follicular stem cells(The National Academy of Sciences of Belarus)	Alopecia More	Phase 2 Clinical
Cultured retinal stem and progenitor cells(The National Academy of Sciences of Belarus)	Age Related Macular Degeneration More	Phase 2 Clinical
Allogenic parathyroid cells(The National Academy of Sciences of Belarus)	Hypoparathyroidism More	Pending